Literature DB >> 29910593

Topical therapies for the treatment of anal high-grade squamous intraepithelial lesions.

Christina Megill1, Timothy Wilkin1.   

Abstract

Anal cancer may be prevented by treating anal high-grade squamous intraepithelial lesions (HSIL). Ablative therapies are the most commonly used treatments, but they may not be appropriate for all patients including those with extensive HSIL or bleeding diastheses. Researchers have studied topical therapies for human papillomavirus related lesions including anal HSIL. These therapies include patient-applied 5-fluorouracil, imiquimod and cidofovir, and provider-applied trichloroacetic acid. This review will discuss literature supporting efficacy of these products, which is based mainly on case series with few controlled trials having been conducted. Side effects are common with patient-applied topical therapy often requiring dose reduction and medication to treat pain. However, treatment discontinuations are infrequent. This review will also discuss some approaches to the use of these products in clinical practice.

Entities:  

Keywords:  Anal dysplasia; Cidofovir; Fluorouracil; Imiquimod; Trichloroacetic acid

Year:  2017        PMID: 29910593      PMCID: PMC5999046          DOI: 10.1053/j.scrs.2017.04.006

Source DB:  PubMed          Journal:  Semin Colon Rectal Surg        ISSN: 1043-1489


  52 in total

1.  Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.

Authors:  J A Johnson; J D Gangemi
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.

Authors:  R Snoeck; M Bossens; D Parent; B Delaere; H Degreef; M Van Ranst; J C Noël; M S Wulfsohn; J F Rooney; H S Jaffe; E De Clercq
Journal:  Clin Infect Dis       Date:  2001-07-26       Impact factor: 9.079

3.  Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study.

Authors:  Peter V Chin-Hong; Eric Vittinghoff; Ross D Cranston; Lynette Browne; Susan Buchbinder; Grant Colfax; Maria Da Costa; Teresa Darragh; Dana Jones Benet; Franklyn Judson; Beryl Koblin; Kenneth H Mayer; Joel M Palefsky
Journal:  J Natl Cancer Inst       Date:  2005-06-15       Impact factor: 13.506

4.  Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males.

Authors:  Stephen E Goldstone; Joshua S Hundert; Jeff W Huyett
Journal:  Dis Colon Rectum       Date:  2007-05       Impact factor: 4.585

5.  Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.

Authors:  Bassam Abdulkarim; Siham Sabri; Eric Deutsch; Heddia Chagraoui; Laurence Maggiorella; Jerome Thierry; François Eschwege; William Vainchenker; Salem Chouaïb; Jean Bourhis
Journal:  Oncogene       Date:  2002-04-04       Impact factor: 9.867

6.  Use of imiquimod 5% cream (Aldara) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002-2005).

Authors:  V L Gill; P J Bergman; K E Baer; D Craft; C Leung
Journal:  Vet Comp Oncol       Date:  2008-03       Impact factor: 2.613

7.  Topical 5-fluorouracil in the management of extensive anal Bowen's disease: a preferred approach.

Authors:  Bruce D Graham; Allen B Jetmore; Jerry E Foote; L Kirk Arnold
Journal:  Dis Colon Rectum       Date:  2005-03       Impact factor: 4.585

8.  External genital warts: diagnosis, treatment, and prevention.

Authors:  D J Wiley; John Douglas; Karl Beutner; Tom Cox; Kenneth Fife; Anna-Barbara Moscicki; Lynne Fukumoto
Journal:  Clin Infect Dis       Date:  2002-10-15       Impact factor: 9.079

9.  Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study.

Authors:  Ole Mathiesen; Sanne K Buus; Marie Cramers
Journal:  Gynecol Oncol       Date:  2007-07-25       Impact factor: 5.482

10.  Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata.

Authors:  G Coremans; V Margaritis; R Snoeck; J Wyndaele; E De Clercq; K Geboes
Journal:  Dis Colon Rectum       Date:  2003-08       Impact factor: 4.585

View more
  3 in total

1.  Design of the ANal Cancer/HSIL Outcomes Research study (ANCHOR study): A randomized study to prevent anal cancer among persons living with HIV.

Authors:  Jeannette Y Lee; Shelly Y Lensing; J Michael Berry-Lawhorn; Naomi Jay; Teresa M Darragh; Stephen E Goldstone; Timothy J Wilkin; Elizabeth A Stier; Mark Einstein; Julia C Pugliese; Joel M Palefsky
Journal:  Contemp Clin Trials       Date:  2022-01-10       Impact factor: 2.226

Review 2.  Anal Squamous Intraepithelial Lesions and Anal Cancer Management in Low Resource Settings.

Authors:  Alexander T Hawkins; Sandy H Fang
Journal:  Clin Colon Rectal Surg       Date:  2022-09-13

3.  Electrocautery ablation of anal high-grade squamous intraepithelial lesions: Effectiveness and key factors associated with outcomes.

Authors:  Michael M Gaisa; Yuxin Liu; Ashish A Deshmukh; Kimberly L Stone; Keith M Sigel
Journal:  Cancer       Date:  2020-01-24       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.